EL7.AI
StocksMedium•16 November 2026•
3 min read

Jaguar Health Posts $9.23 Per-Share Loss as Third-Quarter Revenue Falls

Key Facts

1Basic and diluted loss per share was $9.23 in the quarter ended September 30, 2026.
2Third-quarter revenue fell to $2.343 million from $3.083 million a year earlier.
3Net loss narrowed to $5.830 million from $9.648 million in the year-earlier quarter.
4One customer accounted for about 98% of third-quarter 2026 revenue.
5The accumulated deficit was $409.5 million as of September 30, 2026, and the company said its financing does not alleviate substantial doubt about its ability to continue as a going concern for one year.

Jaguar Health posted basic and diluted losses of $9.23 per share and a net loss attributable to common stockholders of $6.314 million for the three months ended September 30, 2026, according to a filing with the U.S. Securities and Exchange Commission. Revenue was $2.343 million, down from $3.083 million in the year-earlier quarter. Net loss, meanwhile, narrowed to $5.830 million from $9.648 million a year earlier. The results put shrinking revenue alongside an improved net loss, while the reported per-share loss remained large relative to quarterly revenue. In the same filing, the company warned that its cash balances were insufficient to fund its operating plan for one year from the date the financial statements were issued and that it needed additional financing.

Revenue composition shifted sharply between the periods. Jaguar Health reported $1.792 million in licensing revenue in the third quarter of 2026, compared with $42,000 in the third quarter of 2025, while product revenue fell to $551,000 from $3.041 million. The company said about 98% of quarterly revenue came from one customer, Woodward Specialty LLC. Revenue in the year-earlier period came almost entirely from Mytesi sales. The year-over-year comparison therefore reflects a shift from near-total reliance on product sales to concentration of current-quarter revenue in licensing and one customer, according to the filing.

For the nine months ended September 30, Jaguar Health revenue rose to $23.840 million from $8.276 million in the same period of 2025. The company attributed part of its 2026 revenue to the license and supply agreement, which provided $16.0 million in upfront revenue. It added that on February 22 it received a $3.0 million fee to terminate the repurchase option, bringing total revenue from the arrangement to $20.8 million. The arrangement puts the nine-month increase in the context of upfront licensing revenue, alongside the year-over-year decline in third-quarter product revenue. Operating expenses in the quarter were $8.366 million, compared with $10.321 million in the year-earlier period.

Despite the narrower quarterly net loss, company data showed a $6.314 million loss attributable to common stockholders, the basis for calculating the $9.23 per-share loss. The company reported an accumulated deficit of $409.5 million as of September 30, 2026. It said it expects continued losses and negative operating cash flows. It also said its financing plans do not alleviate substantial doubt about its ability to continue as a going concern for one year from the date the financial statements were issued. The filing stated that "cash balances are insufficient to fund our operating plan for one year from the date these consolidated financial statements are issued," and that the company needs additional financing.

The company continues to advance its clinical programs while facing financing needs. It said its Phase 2 study in patients with short bowel syndrome with intestinal failure, underway in Italy and Germany, is expected to report results in the second half of 2027. It also said an open-label exploratory study of crofelemer in adults with type 1 short bowel syndrome and intestinal failure is ongoing, and that positive preliminary results were presented at the American College of Gastroenterology meeting on October 13, 2026. The study was designed to include 6 patients taking the treatment 3 times daily for 12 weeks. Its primary objective is to reduce ostomy output volume. The Phase 2 study results are the future milestone specified in the filing, while the exploratory study remains open and ongoing.

Open on chart